MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
MONTEROSA Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. (Real World Observational Study of STRIDE Regimen for Advanced HCC)
- Hepatocellular Carcinoma
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- AstraZeneca
- Enrolment target
- 200
- Started
- 16 April 2026
- Main results due
- 31 October 2028
- Study sites
- 24
- Registry updated
- 29 September 2026
Can you take part?
- Ages 18 years to 100 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * \- Signed informed consent. * Age ≥ 18 years. * Histologically or radiologically confirmed diagnosis of advanced or unresectable HCC. * BCLC B or C HCC. * Child-Pugh A (score 5 or 6). * Eastern Cooperative Oncology Group (ECOG) Performance Status score 0 or 1. * Planned first-line treatment of advanced/uHCC with STRIDE. Exclusion Criteria: * \- Any previous line of systemic therapy for HCC. * Any prior or concomitant immunotherapy. * Prior allogeneic organ or bone marrow transplant. * Documented active or previous GI bleeding within the previous 12 months. * Main trunk portal vein thrombosis. * Autoimmune disease requiring treatment with immunosuppressive medication. * Known hypersensitivity to the active substance or to any of the STRIDE excipients. * Pregnancy or breastfeeding
What this study is about
In the sponsor’s own words, from the registry.
Italian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiveness, and safety of tremelimumab plus durvalumab in patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic treatment.
Study sites(24)
Research site
Ancona, Italy
Active, not recruiting
Research Site
Ancona, Italy
Recruiting
Research Site
Bergamo, Italy
Recruiting
Research site
Foggia, Italy
Recruiting
Research Site
Foggia, Italy
Recruiting
Research Site
Meldola, Italy
Recruiting
Research site
Milan, Italy
Active, not recruiting
Research Site
Milan, Italy
Recruiting
Research site
Modena, Italy
Active, not recruiting
Research Site
Modena, Italy
Recruiting
Research site
Naples, Italy
Recruiting
Research Site
Naples, Italy
Recruiting
Research Site
Padova, Italy
Recruiting
Research Site
Palermo, Italy
Recruiting
Research Site
Pisa, Italy
Recruiting
Research site
Pozzuoli, Italy
Active, not recruiting
Research Site
Pozzuoli, Italy
Recruiting
Research Site
Roma, Italy
Recruiting
Research site
Rozzano, Italy
Active, not recruiting
Research Site
Rozzano, Italy
Recruiting
Research site
Torino, Italy
Active, not recruiting
Research Site
Torino, Italy
Recruiting
Research site
Verona, Italy
Active, not recruiting
Research Site
Verona, Italy
Recruiting
Showing 24 of 24 sites. 17 of the 24 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07607769. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me